SVN MED OVERVIEW:

SVN Med has developed a **functional** cancer device and has two **issued** patents.

The biomedical device filters and removes over 1000x more cancer cells (circulating tumor cells or CTCs) from the bloodstream than the most advanced technologies on the market (think cancer dialysis). By removing such a large volume of cancer cells, SVN Med can therapeutically inhibit the progression of metastatic cancer spread from solid tumors (breast cancer, lung cancer, prostate cancer, ovarian cancer, pancreatic cancer, colorectal cancer, liver cancer, etc.) and extend life for cancer patients.

Other applications of the technology include diagnostics for very early detection of cancer (by identifying cancer cells in the blood), the ability to create an extremely valuable genomics dataset (by sequencing the cancer cells in the blood), and the ability to remove cancer cells from the blood during and post surgery to remove tumors..

The founders include successful serial entrepreneurs, the youngest and 19th US Surgeon General (Vivek Murthy), ex-Harvard Faculty (Gautam Mukunda), world-renowned scientists (Kim de Mora), and Nobel Laureates (Stephen de Mora).

Merck Distinguished Scientists that have run over 80 clinical trials in oncology and hematology, experts in oncology biostatistics, nephrology experts like the Chairman of Medicine at SUNY, the CEO of a medical device distributor, and prominent Stanford surgeons have all personally invested. Further, WTI, a prestigious 40 year old, $6 Billion Silicon Valley fund has also invested.

SVN MED BUSINESS LINES:



1 THERAPEUTICS:
This application is cancer dialysis to remove cancer cells from the blood and slow down the spread of cancer and extend life.

2 DIAGNOSTICS:
Early detection because solid tumors spread CTCs into the blood well before the tumor has grown to a detectable size. Further, our diagnostics would be meaningfully superior because ALL liquid biopsy diagnostics today rely on capturing just DNA whereas we can actually capture the whole cells (the circulating tumor cells, CTCs) at volume which is impossible to do with existing liquid biopsy technologies.

3 GENOMICS DATA:
Because we are actually capturing the CTCs, we can sequence them to build an unparalleled genomic dataset in terms of both volume of data and type of data.

4 SURGICAL RESECTION ADJUVANT THERAPY:
A known, primary side effect of tumor removal surgery, is that the spike in CTCs that occurs thereafter (due to disruption of the mass of the tumors releasing CTCs into the bloodstream) can accelerate metastasis. Using our device in combination with surgery would enable surgeons to cut out the tumor AND remove the spike in CTCs thereby providing the best of both worlds.

5 SERVICE CENTERS:
Because we have the only functional machine in the world (with two issued patents) that can remove CTCs at therapeutic scale, we can joint venture with clinics (similar to dialysis clinics) as the service is deployed to the market. Unlike kidney dialysis, there are not multiple vendors from which to buy machines (again, we are the only machine that exists that can do this) so we can demand a portion of the service side of the revenue (or portion of ownership) by partnering

SUBSTANTIAL DOWNSIDE PROTECTION:

From a financial standpoint, there is a safety net (hedge) to the business. We are confident that we will be successful in the aforementioned lines of business, but even in the event that we are wrong, we can build a multi-billion business simply selling the device to cancer lab and research facilities around the world because the #1 problem researchers have in studying CTCs is capturing enough of them (both Dana Farber and Memorial Sloan Kettering have successfully used our device to filter, capture, culture, and study CTCs). That business does not require any regulatory approval whatsoever and literally could start tonight. The reason we've chosen to wait is because if we went down that route, the researchers (academics) would begin to publish the genomics data in the public domain. We want to keep the genomics data in-house in a proprietary dataset that we can monetize.

FORWARD-LOOKING STATEMENTS:

The SEC encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. The information in this presentation, material, our website, and our mobile applications contain "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often include words such as "anticipates," "estimates," "expects," "projects," "intends," "plans," "believes", "will", "assume", and words and terms of similar substance in connection with discussions of future operating or financial performance.

The Company's (SVN MED LLC's) forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Important factors that could cause the Company's actual results to differ materially from those in its forward-looking statements include government regulation, economic, strategic, political and social conditions and the following factors: recent and future changes in technology, science, medicine, healthcare, regulatory conditions, governing laws, patient treatment protocols, health insurance reimbursement policies, healthcare payment policies, and the popularity of the Company's content; changes in the Company's plans, initiatives and strategies, and industry acceptance thereof; changes in the plans, initiatives and strategies of the third parties that distribute, license and/or sell the Company's technology; the Company's ability to renew affiliate agreements on favorable terms; competitive pressures, including as a result of structural industry changes, new entrants, advances in competitive technology, business model changes in hospitals and clinics worldwide, economic conditions, pressure from public interest groups, changes in laws and regulations and other societal or political developments; the Company's ability to deal effectively with economic slowdowns or other economic or market difficulties; changes in foreign exchange rates; increased volatility or decreased liquidity in the capital markets, including any limitation on the Company's ability to access the capital markets for debt securities, refinance its outstanding indebtedness or obtain bank financing on acceptable terms; piracy and the Company's ability to exploit and protect its intellectual property rights in and to its content and other products; the failure to achieve the anticipated benefits of the Company's enterprise efficiency initiatives; the effects of any significant acquisitions, dispositions and other similar transactions by the Company; a disruption or failure of the Company's or its vendors' network and information systems or other technology relied on by the Company; the failure to meet earnings expectations; higher or lower than expected valuations; further dilution from additional financings; the adequacy of the Company's risk management framework; changes in U.S. GAAP or other applicable accounting policies; changes in tax, federal communication and other laws and regulations; currency exchange restrictions and currency devaluation risks in some foreign countries; the effect of union or labor disputes; the impact of terrorist acts, hostilities, natural disasters (including extreme weather) and pandemics; and any other act out of the Company's control.

Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise.

THIS IS NOT AN OFFERING LEGEND:

This presentation and/or material, which is being provided on a confidential basis, shall not constitute an offer to sell or the solicitation of any offer to buy which may only be made at the time a qualified offeree receives the Note Purchase Agreement, which contains important information (including investment objective, policies, risk factors, fees, tax implications and relevant qualifications), and only in those jurisdictions where permitted by law. In the case of any inconsistency between the descriptions or terms in this material and the Note Purchase Agreement, the Note Purchase Agreement shall control. These securities shall not be offered or sold in any jurisdiction in which such offer, solicitation or sale would be unlawful until the requirements of the laws of such jurisdiction have been satisfied. This material is not intended for public use or distribution. While all the information prepared in this material is believed to be accurate, the Company makes no express warranty as to the completeness or accuracy, nor can it accept responsibility for errors or omissions, appearing in the material.

CONFIDENTIALITY NOTICE:

This presentation and/or material is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. If you have received this e-mail in error, please notify the Company by return e-mail and destroy the original message and all copies thereof.